Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Dissecting paclitaxel-microtubule association: quantitative assessment of the 2'-OH group.

Sharma S, Lagisetti C, Poliks B, Coates RM, Kingston DG, Bane S.

Biochemistry. 2013 Apr 2;52(13):2328-36. doi: 10.1021/bi400014t. Epub 2013 Mar 19.

2.

Comparison of Epothilone and Taxol Binding in Yeast Tubulin using Molecular Modeling.

Akbari V, Moghim S, Reza Mofid M.

Avicenna J Med Biotechnol. 2011 Oct;3(4):167-75.

3.

A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy.

Kim YH, Muro K, Yasui H, Chen JS, Ryu MH, Park SH, Chu KM, Choo SP, Sanchez T, DelaCruz C, Mukhopadhyay P, Lainas I, Li CP.

Cancer Chemother Pharmacol. 2012 Oct;70(4):583-90. Epub 2012 Aug 12.

4.
5.

Differentiating between models of epothilone binding to microtubules using tubulin mutagenesis, cytotoxicity, and molecular modeling.

Entwistle RA, Rizk RS, Cheng DM, Lushington GH, Himes RH, Gupta ML Jr.

ChemMedChem. 2012 Sep;7(9):1580-6. doi: 10.1002/cmdc.201200286. Epub 2012 Jul 16.

6.

Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone.

Cristofanilli M.

J Oncol. 2012;2012:703858. doi: 10.1155/2012/703858. Epub 2012 May 8.

7.

Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.

Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL.

Invest New Drugs. 2012 Dec;30(6):2364-70. doi: 10.1007/s10637-012-9800-3. Epub 2012 Feb 14.

8.

Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.

Gupta S, Carballido E, Fishman M.

Onco Targets Ther. 2011;4:79-96. doi: 10.2147/OTT.S14107. Epub 2011 Jun 29.

9.

Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence.

Lee F, Jure-Kunkel MN, Salvati ME.

Ther Adv Med Oncol. 2011 Jan;3(1):11-25. doi: 10.1177/1758834010386402.

10.

Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation.

Khrapunovich-Baine M, Menon V, Yang CP, Northcote PT, Miller JH, Angeletti RH, Fiser A, Horwitz SB, Xiao H.

J Biol Chem. 2011 Apr 1;286(13):11765-78. doi: 10.1074/jbc.M110.162214. Epub 2011 Jan 18.

11.
12.

Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone.

Rivera E, Gomez H.

Breast Cancer Res. 2010;12 Suppl 2:S2. doi: 10.1186/bcr2573. Epub 2010 Oct 22. Review.

13.

Microtubule-stabilizing drugs from marine sponges: focus on peloruside A and zampanolide.

Miller JH, Singh AJ, Northcote PT.

Mar Drugs. 2010 Mar 31;8(4):1059-79. doi: 10.3390/md8041059. Review.

15.
16.

Treatment options for breast cancer resistant to anthracycline and taxane.

Moreno-Aspitia A, Perez EA.

Mayo Clin Proc. 2009 Jun;84(6):533-45. doi: 10.1016/S0025-6196(11)60585-5. Review.

17.

Microtubule dynamics as a target in oncology.

Risinger AL, Giles FJ, Mooberry SL.

Cancer Treat Rev. 2009 May;35(3):255-61. doi: 10.1016/j.ctrv.2008.11.001. Epub 2008 Dec 30. Review.

18.

The paclitaxel site in tubulin probed by site-directed mutagenesis of Saccharomyces cerevisiae beta-tubulin.

Entwistle RA, Winefield RD, Foland TB, Lushington GH, Himes RH.

FEBS Lett. 2008 Jul 9;582(16):2467-70. doi: 10.1016/j.febslet.2008.06.013. Epub 2008 Jun 18.

19.
20.
Items per page

Supplemental Content

Write to the Help Desk